

Margery L. S. Gass, M.D.
Curriculum Vitae

POSITIONS:

Consultant Fred Hutchinson Cancer Research Center 1100 Fairview Ave. N. Seattle, WA 98109	Current
Editorial Board, <i>Menopause</i>	Current
Reviewer, <i>Pharmacist's Letter</i> and <i>Prescriber's Letter</i>	2002-present
Trustee, Board of Trustees International Menopause Society	2016-2018
Executive Director The North American Menopause Society 5900 Landerbrook Drive, Suite 390 Mayfield Heights, OH 44124	2010-2015
Consultant, Center for Specialized Women's Health Cleveland Clinic 9500 Euclid Avenue A10 Cleveland, OH 44195	2009-2015
Clinical Professor Dept of Obstetrics & Gynecology, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University Cleveland, OH 44195	2012-2015
Assistant Professor, Associate Professor, Clinical Professor Dept of Obstetrics & Gynecology University of Cincinnati College of Medicine 231 Albert Sabin Way, P.O. Box 670526 Cincinnati OH 45267-0526	1984-2009

EDUCATION and TRAINING:

Residency University Hospital, Cincinnati OH 1980-1984

M.D. University of Cincinnati College of Medicine
Cincinnati OH 1976-1980

20190506

M.A. Miami University Oxford 1969
OH

B.A. DePauw University 1966
Greencastle IN

MEDICAL LICENSURE: State of Ohio 1980-Present

BOARD CERTIFICATION:

American Board of Obstetrics and Gynecology 1986
American Board of Obstetrics and Gynecology - recertification 1996, 2005-17

ACADEMIC APPOINTMENTS:

Clinical Professor, Cleveland Clinic Lerner College of Medicine,
Case Western Reserve University 2012-2015

Professor Clinical Obstetrics and Gynecology 2000-2009
University of Cincinnati, Department of Obstetrics and Gynecology

Associate Professor of Clinical Obstetrics and Gynecology 1995-2000
University of Cincinnati, Department of Obstetrics and Gynecology

Faculty, Center for Women's Studies, University of Cincinnati 1994-2009

Director, University Hospital Menopause and Osteoporosis Center 1990-2009

Assistant Professor of Clinical Obstetrics and Gynecology 1984-1995
University of Cincinnati, Department of Obstetrics and Gynecology

HONORS:

Executive Director Emerita, The North American Menopause Society 2015

Crain's Cleveland Business Women of Note finalist 2011

Distinguished Alumni Award University of Cincinnati College of Medicine 2010

Best Doctors in Cleveland 2010-2015

Patty Brisben Foundation's Award of Excellence in Women's Sexual Health 2009

DePauw University Scientific Advisory Board 2005-2006

20190506

Distinguished Alumni Award Professional Achievement, DePauw University	2004
Best Doctors in America Listing 2012, 2013, 2014	1998,2004,
Best Specialists in the Tri-State Listing (Cincinnati Magazine)	2004
Best Doctors in Cincinnati Listing (Cincinnati Magazine)	2003, 2007-9
Best Doctors in Cleveland Listing (Cleveland Magazine)	2010-2015
Speaking of Women's Health, Honoree, Cincinnati	1998
Women's Studies, University of Cincinnati Distinguished Alumnae Award	1998
American Medical Women's Association Master Faculty on Osteoporosis <u>Residency</u> ACOG District V Junior Fellows 2nd Place Award for research on The Effect of Episiotomy on the Frequency of Vaginal Outlet Lacerations	1991
<u>Medical School</u> Alpha Omega Alpha - The Obstetrics and Gynecology Award to graduating senior medical student <u>DePauw University</u> Alpha Lambda Delta	1980
Mortar Board	1983
Phi Beta Kappa	1963
Merle Rose Walker Language Award	1965
	1966
	1966

PROFESSIONAL MEMBERSHIPS:

American College of Obstetricians and Gynecologists
 American Medical Association
 American Medical Women's Association
 American Society for Bone and Mineral Research
 American Society for Reproductive Medicine
 International Menopause Society
 International Society for the Study of Women's Sexual Health
 New England Obstetrical and Gynecological Society, Honorary
 The Endocrine Society
 The North American Menopause Society

COMMITTEES:

National and International
 US Food and Drug Administration Bone, Reproductive and Urologic
 Drugs Advisory Committee, Special Government Employee 2015-2019
 US Food and Drug Administration Scientific Panel on Labeling Low Dose
 Estrogen-Alone Products for Symptoms of Vulvar and Vaginal
 Atrophy (VVA) 2015

US Food and Drug Administration Scientific Panel on Female Sexual Dysfunction	2014
Member of the Expert Panel of the Position Development Conference of the International Society for Clinical Densitometry	2013
The National Institutes of Health Advisory Committee on Research on Women's Health	2009-2013
The National Institutes of Health National Advisory Council for the National Center for Complementary and Alternative Medicine	2007-2010
The National Institutes of Health Women's Health Initiative Study: Member, Executive Committee	2003-2006
Lead Principal Investigator for the Midwest Principal Investigators	2003-2006
Member, Presentations & Publications Committee	2003-Present
Member, Hormone Therapy Committee	2001-2006
Member, Hormone Therapy Focus Group	2008-2010
The North American Menopause Society Executive Director Transition Committee	2006-2007
Public Affairs Standing Committee	2004-2006
President	2002-2003
Treasurer	1999-2001
Board of Trustee Member	1998-2004
Chair, Scientific Committee for Annual Meeting	2004-2005
Chair-elect, Scientific Committee for Annual Meeting	2003-2004
Co-Chair, Public Affairs Committee	2004-2005
Bylaws Revision Committee	2004
Contract Committee for Employees	2004
Advisory Panel on Hormone Therapy	2003-2004
Chair, Contract Committee for Executive Director	2003
Advisory Panel on Hormone Therapy, Co-Chair	2002
National Menopause Awareness Month Steering Committee	1996
Scientific Program Committee, Annual Meeting	1996-1998
Professional Education Committee	1997-1998
Chair, Professional Education Committee	1998
Chair, First to Know Committee	2002
A Friend Indeed Publications Award Committee	1996, 1997
DePauw University Science Advisory Committee	2004-2005
American Medical Women's Association Committee to develop slide/lecture Committee to develop slide/lecture program on osteoporosis	1995
National Institutes of Health Special Study Section for Centers of Research in Complimentary and Alternative Medicine	1999
NIH Women's Health Initiative Presentations and Publications Committee	2004-present

The Health Alliance of Greater Cincinnati

Alliance Credentialing Verification Organization Policy Committee	1996
<u>University Hospital and the University of Cincinnati College of Medicine</u>	
UH Lab Consolidation Medical Advisory Group	1996-1997
LCME Objectives Committee	1996
Executive Medical Board Budget Committee of University Hospital and the College of Medicine	1991-1996
<u>University of Cincinnati College of Medicine</u>	
Translational and Interdisciplinary Research Strategy Design Team	2007
BIRCWH Advisory Committee	2006
LCME Self Study Medical Students Sub-Committee	2002-2003
Medical Center Research Committee on Complementary Medicine	1998-2000
Alpha Omega Alpha Executive Committee	1990-2000
Mentor, medical student cost effectiveness papers	1998-1999
Objective Structured Clinical Exam (OSCE) Committee	1988-1990
Search Committee for Chair, Department OB/Gyn	1998
McLain Educational Fund Committee	1996-1998
Integrating Curriculum Committee of the Medical School	1986-1989
Search Committee for Chairman, Department of Ob/Gyn	1987
Medical Student Advisor	1984-1998
<u>University Hospital</u>	
Medical Executive Committee	2000
Credentials Committee	1990-2000
Chair	2002-2004
Patient Care Review Committee	1992-1994
Hearing Panel of the Medical Staff	1988
Surgical and Procedural Review Committee	1987-1991
Medical Advisory Committee, University Health Plan, Inc.	1986-1987
<u>Department</u>	
Mentor, resident research project, Christopher Nichols, M.D., A.K. Jain, M.D.	2002-2004
Mentor, resident research project, Rachel Cooper, M.D.	1998-1999
Mentor, resident research project, Christian Froerer, M.D.	1998-1999
OB Special Care Unit Continuous Quality Improvement Committee	1993-1994
Practice Plan Committee	1990-1992
Quality Assurance Committee	1989-1995
Promotion and Tenure Committee	1986-1996
Library Representative, New Acquisitions	1986-1995
Resident Advisor	1984-1990
Merit Increase Committee	1986-1987;1996

RESEARCH and CLINICAL TRIALS (from 1998-2009):

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Determine the Efficacy and Safety of Risedronate (NE-58095) in the Treatment of Postmenopausal Women with Established Osteoporosis-Related Vertebral Deformities. Margery L.S. Gass, M.D., Co-Investigator. 2/28/94-2/28/98.

Effect of Progestogens on Bone and Cognition. Margery L.S. Gass, M.D., Co-Investigator. NIH AG1108. 3/1/94 - 2/28/01

The Women's Health Initiative Trial of the National Institute of Health. , N01-WH-4-2126. Margery L.S. Gass, M.D., Co-Investigator, 9/30/94 - 9/01. Principal Investigator, 9/01-6/09.

Screening Indigent Women for Osteoporosis. Ohio Department of Health, 9/99 – 6/00.

Beyond Endorsed Lipid-Lowering with EBT Scanning (BELLES) Parke-Davis. Margery L.S. Gass, M.D., Co-Investigator. 4/21/00 -02.

A validation study of the Sexual Activity Log, Locke-Wallace Marital Adjustment Test, the Psychological General Well-Being Index (PGWB) and the Profile of Female Sexual Function in hysterectomized and oophorectomized women having the diagnosis of low libido. Margery Gass, Principal Investigator. Procter & Gamble Pharmaceuticals. 12/99-7/00.

A Phase II, randomized double-blind, placebo-controlled, flexible dose, multi-center study to evaluate the efficacy, safety and toleration of oral Viagra administered for 12 weeks to women who are either postmenopausal or post-hysterectomy, who have physiologic levels of estrogen and testosterone and who have been diagnosed with female sexual arousal disorder. Margery Gass, Co-Investigator. 9/25/00 – 3/3/01

Effect of low-dose Cenestin on bone and brain blood flow in menopausal women. \$122,805.04. Duramed/Barr. Margery Gass, M.D., Principal Investigator. 8/9/200 – 5/28/2004.

Women's Health Initiative Memory Study WHI ancillary study. Margery Gass, M.D. Principal Investigator. 9/01-6/09.

Study of Vasomotor Symptoms in Postmenopausal Women Receiving Raloxifene and Oral Estrogen. \$35,506.14. Eli Lilly & Co. Margery Gass, M.D. Principal Investigator. 3/13/2002-2/23/2004.

A study of the Safety and Efficacy of Lasofoxifene in the Treatment of Vaginal Atrophy in Postmenopausal Women. \$110,745.99. Pfizer. Margery Gass, M.D. Principal Investigator. 2/27/0212/18/03.

A Double-Blind, Randomized, Placebo-Controlled Safety and Efficacy Study of

Bazedoxifene/Conjugated/Estrogens Combinations in Postmenopausal Women: Study Type: C - Osteoporosis Prevention I Substudy Without TVU. \$201,995.00. Wyeth. Margery Gass, M.D. Principal Investigator. 5/22/2002-3-31-2006.

Cognitive Complaints in Early Menopause Trial (COGENT) A Pilot Study of the Effect of Hormone Replacement Therapy in Recently Postmenopausal Women with Subject Cognitive Complaints. \$26,438.07. Wyeth. Margery Gass, M.D. Principal Investigator. 6/5/2002-12/17/2003.

A Phase III, Multinational, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300micrograms/day) for 24 weeks and Safety for a further 28 Weeks in Naturally Menopausal Women. \$117,496.36. Procter & Gamble. Margery Gass, M.D. Principal Investigator. 6/19/2002-6/1/2007.

Efficacy and Safety of Black Cohosh in Postmenopausal Women. Investigator initiated study funded by GlaxoSmithKline. \$76,584.90. Margery Gass, M.D. Principal Investigator. 7/2/03-11/1/04.

A Phase III Study of the Efficacy and Safety of Lasofoxifene in the Treatment of Vaginal Atrophy in Postmenopausal Women. \$25,301.31. Pfizer. Margery Gass, M.D. Principal Investigator. 11/19/036/25/04.

A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-223 SR for Relief of Vasomotor Symptoms Associated with Menopause. \$5,931.25. Wyeth. Margery Gass, M.D. Principal Investigator. 12/17/03-5/14/04.

A Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multicenter, 52-week Study to Evaluate the Efficacy and Safety of Transdermal Patches Delivering 150 or 300 mcg/day Testosterone in Menopausal Women with Low Libido Not Receiving Systemic Estrogen. \$136,742.16. Procter & Gamble. Margery Gass, M.D. Principal Investigator. 6/30/2004-3/27/07.

A Double-blind, Randomized, Placebo-controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with Menopause. \$25,793.49. Margery Gass, M.D. Principal Investigator. 8/25/04-9/21/05.

A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 5008a in the Treatment of Moderate to Severe Vasomotor Symptoms Associated with the Menopause. \$41,164.65. Organon. Margery Gass, M.D. Principal Investigator. 12/1/04-5/31/06.

Mammographic Density and Invasive Breast Cancer Study: Women's Health Initiative Ancillary Study. National Cancer Institute. Margery Gass, M.D. Co-Investigator. 3/05-3/06.

A Multicenter, Double-Phase, Randomized, Double-Blind, Placebo-Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study, Evaluating the Effect of Tolterondine ER on Urgency Urinary Incontinence (UI), Urgency, Frequency, Sexual Quality of Life. \$47,905.00. Pfizer. Margery Gass, M.D. Co-Investigator. 3/9/05-8/1/06

Coronary Artery Calcium Study: Women's Health Initiative Ancillary Study. Margery Gass, M.D. Principal Investigator. 6/05-8/05.

Benign Breast Disease Study: Women's Health Initiative Ancillary Study. Margery Gass, M.D. Principal Investigator. 8/05-7/06.

A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations for Treatment of Moderate to Severe Vulvar/Vaginal Atrophy in Postmenopausal Women. \$45,756.25. Wyeth. Margery Gass, M.D. Principal Investigator. 10/19/05-5/10/07.

An Exploratory Study in Healthy Women Volunteers of Childbearing Age to Determine the Normal Premenopausal Variation Pattern and Range of Bone Turnover Markers During the Menstrual Cycle. \$64,407.97. Roche. Margery Gass, M.D. Principal Investigator 2/08/06-7/20/07.

A Randomized, open-label, comparative, multi-center trial to evaluate contraceptive efficacy, cycle control, safety and acceptability of a monophasic COC containing 2.5 mg norgestrel acetate (NOMAC) and 1.5 mg estradiol (E2), compared to a monophasic COC. \$84,972.50. 7/26/06-10/21/08. Organon (Rumba Study). Margery Gass, M.D. Principal Investigator. 7 /26/06-10-21-08.

A Double-Blind, Randomized, Placebo-controlled, Efficacy and Safety Study of DVS SR For Treatment of Vasomotor Symptoms Associated With Menopause. \$7,800.00. Wyeth. Margery Gass, M.D. Principal Investigator. 8 /23/06-4/12/07.

A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and, With Uptitration, 100 Milligrams Daily in Premenopausal Women with Hyposexual Desire Disorder. \$108,481.37. Boehringer-Ingelheim. Margery Gass, M.D. Principal Investigator. 9/5/07-7/14/08.

A twelve month, open-label, safety trial of flibanserin 50 milligrams to 100 milligrams daily in women with Hypoactive Sexual Desire Disorder. \$52,171.82. Boehringer-Ingelheim. Margery Gass, M.D. Principal Investigator. 5 /30/07-9/30/09.

A Randomized, Double-blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 mcg/day) in Naturally Postmenopausal Women with Hypoactive Sexual Desire Disorder. \$45,307.00. Procter & Gamble (Embrace Study). Margery Gass, M.D. Principal Investigator. 8 /8 /07-7/1/09.

A Double-blind, Randomized, Placebo-Controlled Study Assessing the safety and Efficacy of DVS SR for the Treatment of Vasomotor Symptoms Associated with Menopause. \$87,712.40. Wyeth. 7/9/08/2/10. Margery Gass, M.D. Principal Investigator. 7/9/08-8/2/10.

Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene

Acetate/Conjugated Estrogens, Raloxifene and Placebo and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3115A1-303-WW. \$4,876.80. Wyeth. Margery Gass, M.D. Principal Investigator. 2/26/09-3/1/10.

PUBLICATIONS:

Books and Book Chapters:

Rebar RW, Thomas MA, **Gass MLS**, Liu JH. Problems of hormone therapy: Evaluations, follow-up, complications. In: Korenman SG (ed): *The Menopause. Biological and Clinical Consequences of Ovarian Failure: Evolution and Management*. Norwell, Massachusetts: Serono Symposia, USA, 1990:145-56.

Gass MLS. The physiology and pathophysiology of the postmenopausal years. In: Baker VV, Moore T, Rebar RW, Reiter RC (eds), *Gynecology and Obstetrics: An Integrated Approach*. New York: Churchill Livingstone, Inc., 1993:883-98.

Gass MLS, Rebar RW. Menopause. In: *Current Opinion in Endocrinology and Diabetes*. Philadelphia: Current Science, 1994:06-211.

Gass MLS, Mezrow G, Rebar RW. The menopause. In: Sciarra JJ (ed): *Gynecology and Obstetrics*. Philadelphia, J.B. Lippincott Company, 1995.

Gass MLS, Rebar RW. The menopause. In: Sciarra JJ (ed): *Gynecology and Obstetrics*. Philadelphia, J.B. Lippincott Company, Update & Revision (in press) 1998.

Gass MLS, Rebar RW. Demographics of the Aging Population. In: Sciarra JJ (ed): *Gynecology and Obstetrics*. Philadelphia, J.B. Lippincott Company, 1998.

Gass MLS: Precip VI. Primary and Preventive Care – Care of the Elderly, 1999

Gass MLS, Rebar RW. Hormone replacement for the new millennium. In: Penzias AS(ed): *Obstetrics and Gynecology Clinics of North America*, Vol 27(3)September 2000. Philadelphia, W.B. Saunders Company

Liu, James H, **Gass, Margery**. Management of the Perimenopause (Practical Pathways in Obstetrics & Gynecology Series) McGraw-Hill Professional, 2006.

Gass ML. “The Women’s Health Initiative – Data and Discussion” in Lobo RA, *Treatment of the Postmenopausal Woman*. Elsevier, San Diego. 2008.

Paupoo A, **Gass MLS**. “Osteoporosis” in Hillard PA, *The 5-Minute Obstetrics and Gynecology Consult*. Lippincott Williams & Wilkins, Philadelphia, PA. 2008.

Gass MLS. “Menopause” in Hillard PA *The 5-Minute Obstetrics and Gynecology Consult*. Lippincott Williams & Wilkins, Philadelphia, PA. 2008.

Gass, Margery; Manson, JE; Bassuk, SS. Hormone Therapy. In James M. Rippe, M.D., Ed., *Encyclopedia of Lifestyle Medicine and Health*. Thousand Oaks, CA: SAGE Publications. 2012

Gass ML. “Menopause” in *Lifestyle Medicine*, 2nd Edition. James M. Rippe, M.D., Ed. CRC Press, Taylor and Francis Group, Boca Raton, FL. 2013.

Gass M, Khan S. “Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis” Book chapter for Marcus *Osteoporosis*. 2013.

Articles and Position Statements:

Gass MLS. The effect of episiotomy on the frequency of vaginal outlet lacerations. *J Reprod Med* 1986;31:240-4.

Rebar RW, Thomas MA, **Gass MLS**, Liu JH. The menopause: Problems of hormone therapy -- Evaluations, follow-up, complications. Serono Symposia, USA. Edited by Stanley Korenman, 1990:14556.

Gass MLS, Rebar RW. Conspectus: Management of problems during menopause. *Compr Ther* 1990;16:3-10.

Gass MLS. Does abdominoplasty predispose to pelvic relaxation? Letter to Editor. *Plast Reconstr Surg* 1990;86:1240-1.

Gass MLS. Use of ERT in patients with a history of breast cancer. *International Correspondence Society of Obstetricians and Gynecologists* 1991;32:10-12.

Thomas MA, **Gass MLS**, Scott MC, Liu JH. Multiple therapies for vaginal bleeding secondary to large uterine myomas. *Int J Gynaecol Obstet* 36:239-341, 1991.

Gass MLS, Rebar RW, Liu JH. One way to serve the post-menopausal patient. *Ohio Med* 1991;87:458.

Gass MLS, Carey PM. Fetal-maternal bleed in the second trimester of pregnancy: A report of two cases. *J Reprod Med* 1992;37:378-380.

Gass MLS. Hormone replacement therapy and mesenteric thrombosis. *International Correspondence Society of Obstetricians and Gynecologists* 1993;34:2.

Gass MLS. Counseling the Menopause Patient. *Hosp Med* 1994;March:24.

Gass MLS. Hormone replacement therapy in the patient with breast cancer. *International Correspondence Society of Obstetricians and Gynecologists*, September, 1994.

Gass MLS, Rebar RW, Liu JH, Cedars MI. Characteristics of Women Who Continue Using Hormone Replacement Therapy. *Menopause* 1997;4:19-23.

Gass MLS. Use of estrogen replacement therapy in a 34-year-old woman with a history of breast cancer. *International Correspondence Society of Obstetricians & Gynecologists*, November, 1996.

Gass MLS. Natural hormone replacement therapy: does use of estriol prevent breast cancer. *International Correspondence Society of Obstetricians & Gynecologists*. January, 1997.

Gass ML. Osteoporosis and the Gynecologist A Call to Action. *Contemporary Ob/Gyn* 1997.

Gass MLS. Raloxifene. *Southern Medical Journal* 1999;92:1120-3.

Gass MLS. Hormonal Replacement Therapy. *Southern Medical Journal* 1999;92:1124-7.

Froerer C, Liu J, Pesce A, Levin L, **Gass M**. Relationship of Serum and Salivary Androgen Levels to Sexual Well-being in Postmenopausal Women. *Menopause* 1999;6:4.

Gass M, Rebar R. Hormone replacement for the new millennium. *Obstet Gynecol Clin North Am* 2000;27:611-23.

Gass MLS. Premature Menopause: Women with Special Needs, *The Female Patient*, Vol. 25, June, 2000.

Gass MLS, Rebar RW. Adherence and Hormone Replacement Therapy. *ACOG Clinical Practice* Vol 5, No. 6, November/December 2000.

Gass MLS, Taylor MB. Alternatives for women through menopause. *Am J Obstet Gynecol* 2001;185:S4756.

Gass MLS, Liu JH, Rebar RW. The Effect of low dose conjugated equine estrogens and cyclic MPA on bone density. *Maturitas* 2002;41:143-7.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. *JAMA* 2002;288:321-33.

Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 Position Statement of The North American Menopause Society *Menopause* 2003;10:6-12

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, **Gass M**, Lane DL, Rodabough J. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women in the Women's Health Initiative Randomized Trial. *JAMA* 2003;289:3243-53.

Gass M. Impact of WHI conclusions and ACOG guidelines on clinical practice. Osteoporosis Diagnosis and Management post WHI. *Int J Fertil. Women's Medicine Edition.* 2003;48(3),106-10.

Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, **Gass MLS.** Effect of Estrogen plus progestin on global cognitive function in postmenopausal women. *JAMA* 2003;289:2663-72.

Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2003 Position Statement of The North American Menopause Society. *Menopause* 2003;10:497-506.

The Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy. *JAMA* 2004;291:1701-12.

Utian W, **Gass M,** Pickar J. Body Mass index does not influence response to treatment nor does body weight change in response to lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. *Menopause.* 2004;11:306-14.

"The State of the Art in the Management of Osteoporosis" **M Gass** a contributor to Scientific Round Table sponsored by US Department of Health and Human Services and the Office on Women's Health. *Clinician* 2004;22.

Gass M, Rebar R, Cuffie-Jackson C, et al. A Short study in the treatment of hot flushes with buccal administration of 17-Beta estradiol. *Maturitas.* 2004;49:140-7.

Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 Position Statement of The North American Menopause Society. *Menopause* 2004;11(6):589-600.

Stefanick et al. Reanalysis of the Women's Health Initiative Oral Contraceptive Data Reveals No evidence of Delayed Cardiovascular Benefit. *Fertility and Sterility* 2005; 83: 853-4.

Chen Z, PhD, MPH, Maricic M, MD, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, **Gass M,** LeBoff MS. Fracture Risk among breast cancer survivors – Results from the Women's Health Initiative Observational Study. *Arch Intern Med* 2005;165: 552-8.

Ockene JK, Barad DH, Cochrane BB, Larson JC, **Gass M,** et al. Symptom experience after stopping estrogen plus progestin in the Women's Health Initiative. *JAMA* 2005; 294:183-93.

Brunner R. **Gass M,** Aragaki A, et al. Effects of Conjugated Equine Estrogen on Health-Related Quality of Life in Postmenopausal Women with Hysterectomy: Results from the Women's Health Initiative Randomized Clinical Trial. *Arch Intern Med.* 2005;165:1976-86.

Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, **Gass M,** LeBoff MS, Bassford TL. Osteoporosis and Rate of Bone Loss among Postmenopausal Survivors of Breast Cancer: Results from a Subgroup in the Women's Health initiative Observational Study. *Cancer* 2005;104:1520-30.

Cochrane BB, Barad DH, **Gass M**, Brunner RL, Lewis CE, Stefanick ML. WHI Response to Ostrzenski and Ostrzenska. *Am J Obstet Gynecol* 2005;193:1605-6.

Hamdy RC, Chestnut CH, **Gass ML**. Treatment modalities for postmenopausal osteoporosis. *Southern Med J* 2005;98:1000-14.

Gass M, Dawson-Hughes B. Preventing Osteoporosis-Related Fractures: An Overview. *Am J Med* 2006;119(4A):3S-11S.

Jackson RD, LaCroix A, **Gass ML** et al. Calcium plus Vitamin D supplementation and the risk of fractures. *N Engl J Med*. 2006; 354:669-83.

Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, **Gass M**, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR. Venous Thrombosis and Conjugated Equine Estrogen in Women without a Uterus. *Arch Intern Med* 2006;166:772-80.

Silberstein EB, Levin LL, Fernandez-Ulloa M, **Gass ML**, Hughes JH. Bone mineral density (BMD) assessment of central skeletal sites from peripheral BMD and trasonographic measurements: An improved solution employing age and weight in type 3 regression. *J Clin Dens* 2006;9:323-8.

Stovall W, Utian W, **Gass M**, Qu Y, Muram D, Wong M, Plouffe, Jr. L. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. *Menopause* 2007;14:51017.

Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, **Gass M**, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. *N Engl J Med*. 2007;356:2591-602.

Speroff L, **Gass M**, Constantine G, Olivier S, for the Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. *Obstet Gynecol* 2008;111;77-87.

Gass ML, Kagan R, Kohles JD, Martens MG. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. *Menopause* 2008;15:667-75.

Wyrwich KW, Spratt DI, **Gass M**, Yu H, Bobula JD. Identifying Meaningful Differences in Vasomotor Symptoms Among Menopausal Women. *Menopause* 2008;15:698-705.

Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, **Gass M**, Braunstein G, Hirschberg AL, Rodenberg C, Pack S, Koch H, Studd J, for the APHRODITE Study Team. Efficacy and Safety of Testosterone Patches for Treating Hypoactive Sexual Desire Disorder in Menopausal Women not on Estrogen: The APHRODITE Trial. *New Engl J Med* 2008;359:2005-17.

Heiss,G.; Wallace,R.; Anderson,G.L.; Aragaki,A.; Beresford,S.A.; Brzyski,R.; Chlebowski,R.T.; **Gass M.**; LaCroix,A.; Manson,J.E.; Prentice,R.L.; Rossouw,J.;

Stefanick, M.L.; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. *JAMA* 2008;299:1036-45.

Gass M. Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy. *Cleveland Clinic Journal of Medicine* 2008;75(Spl4):S13-6.

McKenzie M, Sikon AL, Thacker HL, **Gass M**, Hodis HN, Jenkins MR. Putting the latest data into practice: case studies and clinical considerations in menopausal management. *Cleve Clin J Med.* 2008 May;75 S4:S25-33.

Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, **Gass M**, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J, for the APHRODITE Study Team. Testosterone for Low Libido in Postmenopausal Women not taking Extrogen. *New Engl J Med* 2008;359:205-17.

Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, **Gass M**, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeeen S, Anderson G, for the WHI Investigators. Breast Cancer after use of Estrogen plus Progestin in Postmenopausal Women. *New Engl J Med* 2009;360:373-87.

LaCroix AZ, Kotchen J, Anderson G, Brzyski R, Cauley JA, Cummings SR, **Gass M**, Johnson KC, Ko M, Larson J, Manson JE, Stefanick ML, Wactawski-Wende J. Calcium plus Vitamin D Supplementation and Mortality in Postmenopausal Women: The Women's Health Initiative Calcium Vitamin D Randomized Controlled Trial. *J Gerontol A Biol Sci Med Sci* 2009;64:559-67.

Gass ML, Bassuk SS, Manson JE. Reassessing Benefits and Risks of Hormone Therapy. *AJLM* 2009;3(1):29-43.

Chlebowski RT, Schwartz AG, Wakelee H, et al. for the Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. *Lancet* 2009;374:1243-51.

Atkinson HH, Rapp SR, Williamson JD, Lovato J, Absher JR, **Gass M**, Henderson VW, Johnson KC, Kostis JB, Sink KM, Mouton CP, Ockene JK, Stefanick ML, Lane DS, Espeland MA. The relationship between cognitive function and physical performance in older women: Results from the Women's Health Initiative Memory Study. *J Gerontol A Biol Sci Med Sci.* 2009;65:300-6.

Lobo RA, Pinkerton JV, **Gass ML**, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. *Fertil Steril.* 2009;92:1025-38.

Carbone LD, Johnson KC, Robbins J, Larson JC, Curb JD, Watson K, **Gass M**, Lacroix AZ. Antiepileptic Drug Use, Falls, Fractures and BMD in Postmenopausal Women: Findings from the Women's Health Initiative (WHI). *J Bone Miner Res.* 2010;25:873-81.

Brunner RL, Aragaki A, Barnabei V, Cochrane BB, **Gass M**, Hendrix S, Lane D, Ockene J, Woods NF, Shagufra Y, Stefanick M. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. *Menopause: The Journal of The North American Menopause Society*. 2010;17:946-54.

Chlebowski RT, Anderson GL, **Gass M** et al. Influence of Estrogen plus progestin on breast cancer incidence and mortality in postmenopausal women. *JAMA*. 2010; 304:1684-92.

Allison MA, Manson JE, Aragaki A, Langer RD, Rossouw J, Curb D, Martin LW, Phillips L, Stefanick ML, Cochrane BB, Sarto G, Barnhart J, O'Sullivan MJ, Johnson KC, **Gass, M**, Trevisan M, Woods NF. Vasomotor symptoms and coronary artery calcium in postmenopausal women. *Menopause: The Journal of The North American Menopause Society*. 2010;17: 1093-266.

Wallace RB, Wactawski-Wende J, O'Sullivan MJ, Larson JC, Cochrane B, **Gass M**, Masaki K. Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. *Am J Clin Nutr*. 2011;94:270-7.

Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski RT, **Gass ML**, Jacobs ET, LaCroix AZ, Lane D, Larson J, Margolis KL, Millen AE, Sarto GE, Vitolins MZ, Wallace RB. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. *Nutr Cancer*. 2011;63:827-41.

Gass M, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, Lane DS, LaValleur J, Ockene JK, Mouton CP, Barad DH. Patterns and predictors of sexual activity among women in the Hormone Therapy Trials of the Women's Health Initiative. *Menopause* 2011;18:1160-71.

Kudish BI, Iglesia CB, Gutman RE, Sokol AI, Rodgers AK, **Gass M**, O'Sullivan MJ, Larson J, AbuSitta M, Howard BV. Risk Factors for Prolapse Development in White, Black, and Hispanic Women. *Female Pelvic Med Reconstr Surg*. 2011;17:80-90.

Harlow SD, **Gass M**, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ. STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. *Menopause* 2012;19:387-95.

Gass ML, Manson JM, Cosman F, et al. The 2012 hormone therapy position statement of: The North American Menopause Society. North American Menopause Society. *Menopause*. 2012;19:257-71.

ACOG Practice Bulletin #129 *Osteoporosis*. **Gass MS** plus Practice Committee. *Obstet Gynecol* 2012;120,718-34.

de Villiers TJ, **Gass MLS**, CJ Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global Consensus Statement on Menopausal Hormone Therapy. *Climacteric* 2013;16:203–204.

Qi L, Nassir R, Kosoy R, Garcia L, Waetjen LE, Ochs-Balcom HM, **Gass M**, Robbins J, Seldin MF. Relationship between hysterectomy and admixture in African American women. *Am J Obstet Gynecol*. 2013;208:279.e1-7.

Gass ML, Bachman GA, Goldstein SR, Kingsberg SA, Liu JH, Martens MG, Pace DT, Pinkerton JV, Shifren, JL. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause*. 2013;20:888-902.

Rillamas-Sun E, LaCroix AZ, Waring ME, Kroenke CH, LaMonte MJ, Vitolins MZ, Seguin R, Bell CL, **Gass M**, Manini TM, Masaki KH, Wallace RB. Obesity and Late-Age Survival Without Major Disease or Disability in Older Women. *JAMA Intern Med*. 2014;174:98-106.

Crandall CJ, Larson J, Gourlay ML, Donaldson MG, LaCroix A, Cauley JA, Wactawski-Wende J, **Gass ML**, Robbins JA, Watts NB, Ensrud KE. Osteoporosis Screening in Postmenopausal Women 50 to 64 Years Old: Comparison of US Preventive Services Task Force Strategy and Two Traditional Strategies in the Women's Health Initiative. *J Bone Miner Res*. 2014;29:1661-6.

Zhao S, Chlebowski RT, Anderson GL, Kuller LH, Manson JE, **Gass M**, Patterson R, Rohan TE, Lane DS, Beresford SA, Lavasani S, Rossouw JE, Prentice RL. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. *Breast Cancer Res*. 2014;26:16:R30.

Manson JE, Goldstein SR, Kagan R, Kaunitz AM, Liu JH, Pinkerton JV, Rebar RW, Schnatz PF, Shifren JL, Stuenkel CA, **Gass ML**, Utian WH; Working Group on Women's Health and Well-Being in *Menopause*. Why the product labeling for low-dose vaginal estrogen should be changed. *Menopause*. 2014;21:911-6.

Utian WH, Schiff I, Kronenberg F, Kronenberg F, Shifren JL, **Gass ML**. The North American Menopause Society at 25 years: celebrating our history and looking to the future. *Menopause*. 2014;21:1029-31.

Portman DJ, **Gass ML**. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. *Menopause*. 2014;10:1063-8.

Shifren JL, **Gass MLS**, for the NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society Recommendations for Clinical Care of Midlife Women. *Menopause*. 2014; 21: 1038-62.

Crandall CJ, Larson JC, Watts NB, Gourlay ML, Donaldson MG, LaCroix A, Cauley JA, Wactawski-Wende J, **Gass ML**, Robbins JA, Ensrud KE. Comparison of Fracture Risk Prediction by the US Preventive Services Task Force Strategy and Two Alternative Strategies in Women 50–64 Years Old in the Women's Health Initiative. *J Clin Endocrinol Metab* 2014;9:4514-22.

Gourlay ML, Overman RA, Fine JP, Ensrud KE, Crandall CJ, **Gass ML**, Robbins J, Johnson KC, LeBlanc ES, Womack CR, Schousboe JT, LaCroix AZ, for the Women's Health Initiative Investigators. Baseline age and time to major fracture in younger postmenopausal women. *Menopause*. 2015;22:58997.

Manson JE, Ames JM, Shapiro M, **Gass ML**, Shifren JL, Stuenkel CA, Pinkerton JV, Kaunitz AM, Pace DT, Kagan R, Schnatz PF, Kingsberg SA, Liu JH, Joffe H, Richard-Davis G, Goldstein SR, Schiff I, Utian WH. Algorithm and mobile app for menopausal symptom management and hormonal/nonhormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society. *Menopause*. 2015;22:247-53.

Gass ML, Maki PM, Shifren JL, Schnatz PF, Kaunitz AM, Shapiro M, Sievert LL. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. *Menopause*. 2015;22:685-6.

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. *Menopause*. 2015;11:1155-74.

Gass ML, Stuenkel CA, Utian WH, LaCroix A, Liu JH, Shifren JL. Menopause. Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey. *Menopause*. 2015;22:1276-85.

Cote ML, Alhadj T, Ruterbusch JJ, Bernstein L, Brinton LA, Blot WJ, Chen C, **Gass M**, Gaussoin S, Henderson B, Lee E, Horn-Ross PL, Kolonel LN, Kaunitz A, Liang X, Nicholson WK, Park AB, Petruzella S, Rebbeck TR, Setiawan VW, Signorello LB, Simon MS, Weiss NS, Wentzensen N, Yang HP, Zeleniuch-Jacquotte A, Olson SH. Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). *Cancer Causes Control*. 2015 26:287-96

Katon JG, Gray KE, Gerber MR, Harrington LB, Woods NF, Weitlauf JC, Bean-Mayberry B, Goldstein KM, Hunt JR, Katon WJ, Haskell SG, McCutcheon SJ, **Gass ML**, Gibson CJ, Zephyrin LC. Vasomotor Symptoms and Quality of Life Among Veteran and Non-Veteran Postmenopausal Women. *Gerontologist*. 2016;56 Suppl 1:S40-53.

Chlebowski RT, Wakelee H, Pettinger M, Rohan T, Liu J, Simon M, Tindle H, Messina C, Johnson K, Schwartz A, **Gass M**, Wactawski-Wende J. Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. *Clin Lung Cancer*. 2016;17:10-7.

Washington DL, Bird CE, LaMonte MJ, Goldstein KM⁴, Rillamas-Sun E, Stefanick ML, Woods NF, Bastian LA, **Gass M**, Weitlauf JC. Military Generation and Its Relationship to Mortality in Women Veterans in the Women's Health Initiative. *Gerontologist*. 2016;56 Suppl 1:S126-37.

Britton T, Brinton LA, Anderson GL, Pfeiffer RM, Falk RT, Strickler HD, Sliessoraitis S, Kuller LH, **Gass ML**, Fuhrman BJ, Xu X, Wentzensen N. Circulating estrogens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. *Cancer Epidemiology, Biomarkers & Prevention*. In press, 2016.

Drieling, R. LaCroix A, Beresford S, Boudreau D, Kooperberg C, Chlebowski R, **Gass M**, Crandall C, Womack C, Heckbert S. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: Findings From the Women's Health Initiative. *Menopause*. 2016;23:1168-1175.

Brinton LA, Trabert B, Anderson GL, Falk RT, Felix AS, Fuhrman BJ, **Gass ML**, Kuller LH, Pfeiffer RM, Rohan TE, Strickler HD, Xu X, Wentzensen N. Serum estrogen and estrogen metabolites and endometrial cancer risk among postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2016;25:1081-9.

Shadyab AH, **Gass ML**, Stefanick ML, Waring ME, Macera CA, Gallo LC, Shaffer RA, Jain S, LaCroix AZ. Maternal Age at Childbirth and Parity as Predictors of Longevity Among Women in the United States: The Women's Health Initiative. *Am J Public Health.* 2017;107:113-9.

Shadyab AH, Macera CA, Shaffer RA, Sonia Jai S, Gallo LC, **Gass MLS**, Waring ME, Stefanick ML, LaCroix AZ. Ages at Menarche and Menopause and Reproductive Lifespan as Predictors of Exceptional Longevity in Women: The Women's Health Initiative. *Menopause* 2017;24:35-44.

Gourlay M, Overman R, Fine JP, Crandall CJ, Robbins J, Schousboe JT, Ensrud KE, LeBlanc ES, **Gass ML**, Johnson KC, Womack CR, LaCroix AZ. Time to clinically relevant fracture risk scores in postmenopausal women. *Am J Med* 2017;130:862.e15-862.e23.

Poornima IG, Mackey RH, Allison MA, Manson JE, Carr JJ, LaMonte MJ, Chang Y, Kuller LH; WHI and **WHI-CAC Study Investigators**. Coronary Artery Calcification (CAC) and Post-Trial Cardiovascular Events and Mortality Within the Women's Health Initiative (WHI) Estrogen-Along Trial. *J Am Heart Assoc.* 2017;6: e006887.

Gass M, Larson J, Cochrane B, Manson JE, Lane D, Barnabei V, Ockene J, Stefanick ML, Mouton C. Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials. *Menopause.* 2018;25:252-64.

Haring B, Crandall CJ, Carbone L, Liu S, Li W, Johnson KC, Jean Wactawski-Wende J, Shadyab AH, **Gass ML**, Kamensky V, Cauley JA, and Wassertheil-Smoller S. Lipoprotein(a) plasma levels, bone mineral density and risk of hip fracture: a post-hoc analysis of the Women's Health Initiative, USA. *BMJ Open.* 2019;9(4):e027257.

Hall PS, Nah G, Vittinghoff E, Parker DR, Manson JE, Howard BV, Sarto GE, Gass ML, Sealy-Jefferson SM, Salmoirago-Blotcher E, Stefanick ML, Shadyab AH, Van Horn LV, Park K, and Parikh NI. Relation of Pregnancy Loss to Risk of Cardiovascular Disease Among Parous Postmenopausal Women (From the Women's Health Initiative). *Am J Cardiol* 2019;123(10):1620-1625.

Abstracts:

Gass M, Rebar R, Cuffie C, Cedars M, Lobo R, Shoupe D, Judd H, Clisham P, Buyalos R. A placebocontrolled, double-blind dose response study of the efficacy and safety of 17 β -estradiol buccal tablets in the treatment of hot flushes. North American Menopause Society, Montreal Canada, 9/25/91.

Gass MLS, A clinical trial of the effectiveness of low dose hormone replacement therapy (HRT) as a means to arrest bone loss in postmenopausal women. Society for Gynecologic Investigation, Chicago, IL, 3/23-25/94.

Gass MLS, Liu J, Cedars MI, Rebar RW. Predictors of compliance with hormone replacement therapy (HRT). North American Menopause Society, Washington, DC, 9/22/94.

Gass MLS, Rupich R, Georgian-Smith D, Steiner M. The effect of hormone replacement therapy on breast symptomatology. North American Menopause Society Annual Meeting, San Francisco, CA, 9/95.

Rupich RC, Mantus DS, O'Donnell TP, **Gass MLS**. Does self-reported height loss predict prevalent vertebral fractures? American Society for Bone and Mineral Research Annual Meeting, Baltimore, MD, 9/95.

Liu JH, Tsang R, **Gass MLS**, Kao L, Muse K. Identification of women at risk for osteoporosis with bone biomarkers during early menopause. American Society for Bone and Mineral Research Annual Meeting, Seattle, WA, 9/9/96.

Liu JH, Tsang R, **Gass MLS**, Muse K. Physiologic changes in the GH-adrenal-ovarian axes in early menopause and bone mineral density. 10th International Congress of Endocrinology, San Francisco, CA, 1/17/96.

Gass M, Liu JH, Rebar RW. A prospective study of the effect of 0.3 mg versus 0.625 mg conjugated estrogens on bone mineral density. North American Menopause Society. Toronto, Canada, 9/16/98.

Froerer C, Liu J, Pesce A, Levin L, **Gass M**. Relationship of Serum and Salivary Androgen Levels to Sexual Well-being in Postmenopausal Women. The North American Menopause Society Annual Meeting, New York City, NY, 9/23/1999.

Gass M, Fernandez M, Silberstein E, Levin L. Comparison of 3 peripheral bone density machines to central DEXA. World Congress on Osteoporosis. Chicago, IL, June 15, 2000.

Silverman SL, **Gass M**, McIlwain H. Risedronate is well tolerated in osteoporotic patients, including those older than 80 years. *Obstet Gynecol* 2002;99S:58S-59S.

Broy S, **Gass M**, McIlwain H. Residronate results in rapid and consistent risk reduction of vertebral and nonvertebral fractures. *Obstet Gynecol* 2002;99S:59S.

Chen Z, Maricic M, Bassford TL, Ritenbaugh C, Lopez AM, Leboff MS, **Gass M**, Barad DH. Increased Fracture risk among breast cancer survivors. American Society of Bone Mineral Research Annual Meeting, Minneapolis, MN, September 2003.

Jain AJ, **Gass M**. Self reported behavior changes after heel DEXA screening. Society for Gynecologic Investigation 51st Annual Scientific Meeting. Houston, TX. 3-25-04

Cochrane B, Ockene J, Barad D, Larson J, Wassertheil-Smoller S, **Gass M**, et al. Menopausal symptoms reported by women after stopping study pills in the Women's Health Initiative (WHI) estrogen-plus-progestin (E+P) clinical trial. *Menopause* 11:667, 2004.

Bachmann G, **Gass M**, Moffett A, et al. Lasofoxifene Improves Symptoms Associated with Vaginal Atrophy. North American Menopause Society Annual Meeting, October, 2004. *Menopause* 11:667, 2004.

Gass M, Cochrane B, Ockene J, et al. Sexual Function after Discontinuing Study Pills among Women's Health Initiative (WHI) Estrogen-Progestin (E+P) Trial Participants. North American Menopause Society Annual Meeting, October, 2004. *Menopause* 11:667, 2004.

Zientek D, **Gass M**. Comparison of post hormone therapy behavior between women in the Women's Health Initiative and women from a private practice in the same community. North American Menopause Society Annual Meeting, October, 2004. *Menopause* 11:667, 2004.

McCormick BA, Liu JH, **Gass ML**, Thomas MA, Robins JC. Low dose conjugated estrogens do not affect cerebral blood flow. Abstracts of the 50th Annual Meeting of the Society of Gynecologic Investigation. Houston, TX, 2004.

Bachmann G, Simon J, **Gass M**, Kagan R, Spino C, Barcomb L. Lasofoxifene Improves Symptoms of Vaginal Atrophy: Results of a Phase 3 Randomized, Placebo-Controlled Trial. The North American Menopause Society 16th Annual Meeting, San Diego, CA 9-28-05.

Bachmann GA, Barr C, **Gass ML**. Ibandronate reduces fracture rates in patients younger than 60 years with low lumbar spine bone mineral density. ACOG Annual Meeting, Washington, DC, May 6-10, 2006.

Derman RJ, Kohles, JD, **Gass ML**. Physiologic pattern of xCTX in relation to the menstrual cycle of healthy women. International Society of Clinical Densitometry Annual Meeting, Tampa, FL, March 417, 2007.

Gass M, Olivier S, Constantine G. Efficacy and Safety of Desvenlafaxine Succinate for Treatment of Menopausal Vasomotor Symptoms. ACOG 2007, San Diego, CA, May 5-9, 2007.

Gass M, Muse K, Bobula J, Yu H. Sexual Function in Women Treated with Desvenlafaxine Succinate for Menopausal Vasomotor Symptoms. ACOG 2007, San Diego, CA, May 5-9, 2007.

Gass M, Spratt D, Bobula J, Yu H, Olivier S. Meaningful Improvement in Menopausal Vasomotor Symptoms with Desvenlafaxine Succinate. Society of Obstetricians and Gynecologists of Canada Annual Meeting, Ottawa, 2007. Oral Presentation.

Kagan R, **Gass M**, Williams RS, Olivier, S, Pickar J. Effects of the Tissue Selective Estrogen Complex Bazedoxifene and Conjugated Estrogens on Vulvar/Vaginal Atrophy and Sexual Function in Postmenopausal Women. North American Menopause Society Annual Meeting, Dallas, TX, 2007.

Chlebowski RT, et al. (**Gass, co-author**). Estrogen Alone and Lung Cancer in Postmenopausal

Women. Society for Gynecologic Investigation Annual Meeting. San Francisco, March 15, 2010.

Gass M, Stuenkel C. Results From 2010 NAMS Survey on Use of Compounded & Off-label Hormone Products. Annual Meeting of The North American Menopause Society. Washington, DC, September 21, 2011.

Stuenkel C, **Gass M**. Results from 2010 NAMS Survey on Secondary Transfer of Transdermal Estrogen Preparations. Annual Meeting of The North American Menopause Society. Washington, DC, September 21, 2011.

Rillamas-Sun E, LaCroix AZ, Kroenke CH, Waring ME, LaMonte MJ, Vitolins MZ, Bell CL, Manini TM, Masaki KH, Seguin R, Curb JD, **Gass M**, and Wallace RB. "Obesity and the Probability of Surviving to Age 85 Years without Major Disease or Disability in the Women's Health Initiative." The Gerontological Society of America 64th Annual Meeting, Boston, MA, November 2011.

Chlebowski RT, Anderson GL, Kuller LH, Aragaki AK, Manson JE, Stefanick ML, Johnson K, **Gass M**, et al. Estrogen plus progestin (E+P) and breast cancer incidence and mortality. American Society of Clinical Oncology. Chicago June 1, 2012.

Chlebowski R, Wakelee H, Rohan T, Liu J, Simon MS, Tindle H, Messina C, Wactawski-Wende J, Johnson K, Schwartz A, **Gass M**. Estrogen and progestin (E+P) and lung cancer incidence and mortality by smoking status in the Women's Health Initiative (WHI). American Society of Clinical Oncology, Chicago, June 2, 2013.

Gourlay, et al. Time to Fracture. American Society of Bone Mineral Research, Baltimore, MD, October 4, 2013.

Katon, et al. Vasomotor symptoms, depression, obesity, and health related quality of life among Veteran and non-Veteran postmenopausal women. Oral presentation at Association of Psychosomatic Medicine 2015 Annual Meeting, New Orleans , LA, November 11-14, 2015.

Kelley EL, Cannell MB, **Gass M**, et al. Association between Verbal/Physical Abuse and Sexual Satisfaction among Postmenopausal Women in the Women's Health Initiative (WHI). International Society for the Study of Women's Sexual Health. San Diego, CA. February 9, 2018.

PROFESSIONAL ACTIVITY:

Course director and Moderator: Current Concepts in the Evaluation and Treatment of Osteoporosis, Cincinnati OH, 4/26/91

Course Director and Speaker: Symposium on Current Concepts in the Evaluation and Treatment of Osteoporosis, Cincinnati OH, 4/17/96

Course Co-Director: Annual Bone Day Symposium. University of Cincinnati, Cincinnati, OH, 2000-2008

Editor of *Menopause The Journal of the North American Menopause Society*, 2010-2015

Editorial Board, *Menopause*, 1998 to present

Editor of *Menopause Management*, 2010; Editorial Board, 1998-2010

Reviewer for *Climacteric*, 2016-present

Reviewer for *Obstetrics and Gynecology*, 1986, 1998, 1999

Reviewer for *Adolescent and Pediatric Gynecology*, 1987-1989

Reviewer for *American Journal of Obstetrics and Gynecology*, 1998

Reviewer for *International Journal of Gynecology and Obstetrics*, 1998, to present

Reviewer for *Menopause The Journal of the North American Menopause Society*, 1998

Scientific Session: Cutting Edge Research & Health Care at UC College of Medicine, Program Coordinator for University of Cincinnati Medical Alumni Day, Cincinnati, OH, 5/19/95

Specialty Consultant for *Pharmacist's Letter/Prescriber's* 2003- present

Consensus Committee North American Menopause Society. Consensus statement on the use of hormone replacement therapy, 1998

Advisor, Committee Member, Women's Studies Master's Project and oral examination for Kelly Smith, University of Cincinnati, 2000

Independent study supervisor, Women's Studies, Donna Corday, spring 2001

Advisor, Committee Member, Women's Studies Master's Project and oral examination Tasha Dubriwny, University of Cincinnati, 2001

Moderator, Menopause Session. Update in Obstetrics & Gynecology. Cincinnati, OH. August 8, 2001

Symposium Moderator, The Role of Androgen Therapy in Postmenopausal Women. North American Menopause Society Annual Meeting. New Orleans, October 5, 2001.

Quiz the Experts Panel. North American Menopause Society Annual Meeting. New Orleans. October 6, 2001

Moderator, Symposium on Clinical Issue in Gynecology: New Developments

Roundtable discussion leader: Managing Osteoporosis as a Gynecologist. ACOG Annual Clinical Meeting, Los Angeles, May 4, 2002

Women and Cardiovascular Disease: A Guide to Sex and Gender Differences. Advisory Committee. An internet based learning site for medical students on the topic of sex and gender differences in cardiovascular disease. May 2002

Course Co-Director, Care of the Female Patient. Southern Medical Association. Kiawah Island, SC, July 8-12, 2002

Faculty for Scientific Roundtable “The State of the Art in the Management of Osteoporosis”. The Office of Women’s Health of the U.S. Department of Health and Human Services and Columbia University. Washington, DC. July, 2003

Course Co-Director, Care of the Female Patient. Southern Medical Association. Kiawah Island, SC, July 7-11, 2003

Editorial Board: Association of Professors of Gynecology and Obstetrics (APGO) Educational Series on Women’s Health Issues – Current Strategies for Managing Osteoporosis. CME activity, Case Studies, and Slide-Lecture set. January 2004

Course Director and Moderator: Update on Midlife Women’s Health. University of Cincinnati College of Medicine, Cincinnati, OH. January 17, 2004

Course Co-Director, Care of the Female Patient. Southern Medical Association. Kiawah Island, SC, July 26-30, 2004

Invited participant: "Beyond Menopause: Standardization of Terms for Characterizing the Menopausal Transition and Hormone Therapy" sponsored by the NIH Office of Research on Women's Health and National Institute on Aging, and the FDA Office of Women's Health. July 15, 2004, NIH, Bethesda, MD

Reviewer, *Merck Medicus* 2004

Invited presenter: “Women’s Health Research Roundtable: Looking to the Future” Office of Research on Women’s Health. National Institutes of Health, Bethesda, MD. November 17, 2004

Cincinnati Interdisciplinary Women's Health Research Career Training Grant Co-Collaborator: Margery Gass, MD Begin: 9/02/05

“Integrated Menopausal Therapy” Luncheon discussion at American Society for Reproductive Medicine, New Orleans, LA. October 25, 2006

Reviewer, Merck Manual Professional Edition 2006; 2012-2016

Reviewer, Merck Manual Home Edition 2007; 2012-2016

Technical Expert Panel (TEP) for an evidence synthesis of “Nonpharmacologic Treatments for Menopause-Associated Vasomotor Symptoms” commissioned by the Department of Veterans Affairs (VA), Health Services Research and Development (HSR&D), and conducted by the Durham Evidence-based Synthesis Program (ESP), 2015

SELECTED PROFESSIONAL PRESENTATIONS:

"Women and Cardiovascular Disease," Helping Women Take Control: Enhanced Quality of Life after Menopause, Live Interactive Television Broadcast, National Press Club, Washington, DC, 5/31/96.

"Osteoporosis and the Gynecologist," Grand Rounds at Ohio State University, Columbus OH, 12/12/96.

"A Practical Approach for Using Diagnosis Tests for Treatment of Osteoporosis," Diagnostic Strategies for Osteoporosis, Ohio State University, Columbus, OH 4/19/97.

"Women's Health Centers: The Wave of the Future?", Great Expectations: Practice Management Essentials for Obstetrics and Gynecology Residents, Las Vegas, NV ACOG 5/1/97.

"Osteoporosis and the Gynecologist", Grand Rounds, University MacDonal Women's Hospital, Cleveland, OH, 6/12/97.

"The Role of Calcium and Vitamin D in Osteoporosis," Inaugural Conference on Osteoporosis: Diagnosis, Management & Prevention, Southern Medical Association, Amelia Island, FL, 02/20-22/98.

"Hormone Replacement Therapy – Osteoporosis and CVD," American College of Physicians, San Diego, CA, 04/02/98.

"Choices at Menopause," "Debate on the HERS Study," "Memory and Menopause," Jamaica Menopause Society, Kingston, Jamaica, 11/05-07/99.

"Raloxifene vs Estrogen Debate," and "Osteoporosis," Grand Rounds Panelist. Southern Medical Association 93rd Annual Meeting, Dallas, TX, 11/11/99.

"HRT: The Plethora of Possibilities" Ohio State University Grand Rounds. Columbus, OH. October 26, 2000.

American College of Obstetricians and Gynecologists Annual Clinical Meeting 2001 Annual Meeting Interactive session: "Challenging Cases with Hormone Replacement Therapy". Chicago, 2001.

American College of Obstetricians and Gynecologists Annual Clinical Meeting 2001 Special Interest Groups Meeting for North American Menopause Society speaker: "Is there a way to improve adherence with HRT?"

Lecturer, North American Menopause Society Menopause Basics Course at the annual meeting, New Orleans, October 3, 2001.

"Managing Osteoporosis as a Gynecologist". Grand Rounds, University of Virginia, Charlottesville, VA. April 3, 2002.

ACOG postgraduate course: Care of the Perimenopausal Female. Three presentations: “Negotiating the perimenopause transition”. “Managing Osteoporosis as a gynecologist”. “Hormones and breast cancer”. Annual Clinical Meeting. Los Angeles, May 4-5, 2002.

“Solving the Dilemmas – Hormone Replacement Therapy: Challenging Cases – an Interactive session with audience response system”. ACOG Annual Clinical Meeting. Los Angeles, May 4-5, 2002.

“New Therapy Options for HRT: Designing the therapy to fit the diabetic patient”. American Diabetes Association annual meeting. San Francisco, 6-15-02.

“Report of the North American Menopause Society Advisory Panel on Hormone Therapy”. North American Menopause Society Annual Meeting. Chicago, October 4, 2002.

“Hormones, Statins and Cardiovascular Disease”. American Society of Reproductive Medicine Post Graduate Course, Seattle, October 13, 2002.

“Hormone Therapy and Cancer”. American Society of Reproductive Medicine Post Graduate Course, Seattle, October 13, 2002.

“An Overview of the WHI study and its clinical implications”. Symposium. American Society of Reproductive Medicine Annual Meeting, Seattle, October 13, 2002.

“Safety and Tolerability of HT/ET, Weighing the risks and benefits”. Symposium. American Society of Reproductive Medicine Annual Meeting, Seattle, October 15, 2002.

“The Women’s Health Initiative – Why Should We Believe the Results?” Symposium. International Society of Clinical Densitometry. Los Angeles. February 13, 2003.

Fourth Annual University of Cincinnati Bone Day: “Estrogen: What now, What in the Future?” Cincinnati, April 25, 2003.

American College of Obstetricians and Gynecologists Annual Clinical Meeting Post Graduate Course: Care of the Perimenopausal Female. Three presentations: “Negotiating the Menopause Transition” “Managing Osteoporosis as Gynecologists” and “Hormones and Breast Cancer”. New Orleans, May 26-27, 2003.

American College of Obstetricians and Gynecologists Annual Clinical Meeting Interactive Sessions (2): “Solving the Dilemmas – Hormone Replacement Therapy: Just when is it indicated? Difficult cases”. New Orleans, May 29, 2003.

American College of Obstetricians and Gynecologists Annual Clinical Meeting Symposium: “Clarifying the Role of Hormone Therapy: The Experts Debate”. New Orleans, May 28, 2003.

American College of Obstetricians and Gynecologists Annual Clinical Meeting Symposium: The Osteoporosis Imperative: Emerging Paradigms for Bone Preservation and Fracture Reduction. “The Quagmire of Hormone Therapy: What Have We Learned from Recent Clinical Studies?” New Orleans, May 29, 2003.

11th Annual Congress on Women's Health. "HRT: Picking up the Pieces after the Women's Health Initiative". Hilton Head, SC. June 2, 2003.

Department of Health and Human Services. Two presentations: "WHI and Osteoporosis". "Switching from HRT". Washington, DC. July 28-29, 2003.

National Medical Association: "WHI and Osteoporosis – current treatment guidelines". Philadelphia. August 5, 2003.

"How has WHI changed our thinking about hormone therapy?" Endocrinology Grand Rounds. Columbia University, New York, NY. October 31, 2003.

"What has the WHI taught us about breast, gynecological and cognitive health in the menopause?" New Insights and Controversies in Post-Menopausal Health. Columbia University CME program. New York, NY. November 1, 2003.

"Hormone Therapy – What is the Evidence?" and "New Technologies in Female Contraception" at the Southern Medical Association Annual Meeting. Atlanta, GA. November 8, 2003.

"Managing Osteoporosis after the Women's Health Initiative". Austrian Society for Bone Mineral Research. Vienna, Austria. November 27, 2003.

"North American Menopause Society Estrogen Progestin Position Statement". International Menopause Society Workshop. Vienna, Austria. December 1, 2003

"Quality of life and symptoms associated with hormonal therapy" American College of Preventive Medicine Annual Meeting. Orlando, FL. February 18, 2004.

"The WHI Hormone Therapy Legacy" Women and Cancer symposium. Memorial Sloan-Kettering Cancer Center, New York, NY. March 4, 2004.

"HT and the WHI". University of South Carolina Medical Center reproductive endocrinology symposium. Charleston, SC. March 15, 2004.

"How the WHI changes clinical practice". Yale University Endocrinology Grand Rounds. New Haven, CT, March 19, 2004.

"What the WHI can and cannot say about quality of life". 5th International Symposium on Menopause and Women's Health. Lorinzini Foundation. Florence, Italy. April 22, 2004.

"Managing Menopause in Light of the new WHI data" The Texas Medical Association Annual Meeting. Austin, TX. May 14 2004.

New Scientific Evidence & Implications for Women's Health and Update on NIH Women's Health Initiative" Women's Health and Wellness Symposium. Strategic Research Institute. Iselin, N.J. July 15, 2004.

"Current Concepts in the Diagnosis and Treatment of Vulvovaginal Atrophy" 5th Annual Amsterdam Menopause Symposium, Amsterdam, The Netherlands, October 3, 2004.

"The WHI Study: An Update" in Televised symposium on "Osteoporosis: from Bone Biology to Prevention and Treatment Strategies". New York City, NY, October 30, 2004.

"Lessons Learned from Recent Studies" International Menopause Society Triennial Meeting. Buenos Aires, Argentina. 10-19-05.

"Relationship of Age to VTE in the Hormone Trials of the WHI" International Menopause Society Triennial Meeting. Buenos Aires, Argentina. 10-19-05.

"Menopause Management in the USA after WHI Reports" Japan Menopause Society. Tokyo, Japan. 1112-05.

"Role of Hormone Therapy in Osteoporosis in Post-WHI Environment" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Baltimore, MD, March 11, 2006.

"Complementary and Alternative Medicine Guidelines" Presentation at a meeting of PHRMA and the Food and Drug Administration. Bethesda, MD. December 1, 2005.

"State of the Science: A Review of Menopause-related symptoms" American College of Obstetricians and Gynecologists Annual Meeting. Washington, DC. May 8, 2006.

"Estrogen and Cardiovascular Disease" 28th Annual Meeting of the American Society for Bone and Mineral Research. Philadelphia, PA. September 16, 2006.

"Tailoring Hormone Therapy" North American Menopause Society Annual Meeting. Nashville, TN. October 10, 2006.

"Integrated Menopausal Therapy" Roundtable. American Society for Reproductive Medicine Annual Meeting. New Orleans, October 25, 2006.

"Case-Based Panel Discussion". National Osteoporosis Foundation 7th Annual Interdisciplinary Symposium on Osteoporosis. Washington, DC. April 21, 2007.

"The Scope of osteoporosis from diagnosis to treatment". Symposium at the American College of Obstetricians and Gynecologists Annual Meeting. San Diego, May 7, 2007.

"Treating Low Desire in Women: Advances in Pharmacotherapy". 6th Annual Psychopharmacology Update. University of Cincinnati, Cincinnati, OH, October 6, 2007.

Postgraduate Course at the Annual Meeting of the American Society for Reproductive Medicine Washington, DC, October 13, 2007: 1) "Assessing Bone Strength and Fracture Risk", and 2) "When to Treat, to Re-Evaluate, and to Change Treatment".

"Conveying Necessary Information Regarding Risks and Benefits to Patients". North American Menopause Society Annual Meeting, Orlando, Florida, September 26, 2008.

"Hormone Replacement Therapy – Controversies and Dilemmas: An overview of the WHI Data". Symposium on Controversies & Dilemmas in Women's Health. Cincinnati, OH, October 11, 2008.

"The Distilled Message from WHI for My Patients". ACOG District V Annual Meeting, Cincinnati, OH, October 19, 2008.

"Case Studies - Early Postmenopausal Women and Bone" National Osteoporosis Foundation Interdisciplinary Symposium on Osteoporosis, Washington DC, April 4, 2009.

"Evaluating Patients for Postmenopausal Osteoporosis." Postgraduate Course, ACOG, Chicago, Illinois, May 4, 2009.

"The Great Debate: Hormone Therapy Yea or Nay." Society for Gynecologic Investigation Annual Meeting, Orlando, Florida, March 27, 2010.

"The Hormonal Mysteries of Breast Cancer" Cleveland Clinic Women's Cancers Symposium. Cleveland, OH, May 7, 2010.

"Hormones and Breast Cancer" Congreso Latinoamericano en Climaterio y Menopausia. Cancun, Mexico. May 29 - June 2, 2010.

"The 2010 NAMS HT Position Statement: Treating the Peri - & Postmenopause Population" The North American Menopause Society Annual Meeting, Chicago, Illinois. October 8, 2010.

"Current Facts and Nuances in Hormone Therapy." Ohio State University Department of Obstetrics and Gynecology Grand Rounds. Columbus, Ohio. November 18, 2010.

"Evaluating Patients for Postmenopausal Osteoporosis." Postgraduate Course, American Congress of Obstetricians and Gynecologists Annual Meeting, Washington DC, May 2, 2011.

"Update on Postmenopausal Hormone Therapy." Ohio State University Endocrinology Update, Columbus, Ohio, May 13, 2011.

"Managing Menopausal Symptoms." Case Western Reserve University School of Medicine Department of Family Practice Annual Meeting, Cleveland, Ohio. June 1, 2011.

"Current Facts and Nuances in Hormone Therapy." The North American Menopause Society Symposium at the International Menopause Society meeting, Rome, Italy, June 10, 2011.

"Hormones and Breast Cancer." Asociación Mexicana para el Estudio del Climaterio. Congreso Internacional de Climaterio. Mexico City, Mexico. August 25, 2011.

"The Nuances of Hormone Therapy" Asociación Mexicana para el Estudio del Climaterio. Congreso Internacional de Climaterio. Mexico City, Mexico. August 25, 2011.

"Guidelines for Treatment and Current HT Position Statement of The North American Menopause Society." American College of Clinical Pharmacology Annual Meeting. Chicago, Illinois, September 13, 2011.

"Perimenopause Management." Medical College of Wisconsin: Update in Clinical Endocrinology. Milwaukee, Wisconsin, October 15, 2011.

"Managing Nuances of Hormone Therapy." American Osteopathic Association Annual Meeting. Orlando, Florida. October 30, 2011.

"Perimenopause Management" in Update on Women's Health Symposium, University of Cincinnati, Cincinnati, Ohio, March 2, 2012.

"Update on Hormone Therapy: Public Opinion and Policy. Meharry Medical College, Nashville, Tennessee. April 19, 2012.

"Bioidentical Hormones - What you and your patient should know." ACOG Annual Meeting Menopause Special Interest Group. San Diego, California. May 8, 2012.

"A Proactive Approach to Sexual Dysfunctions." Cleveland Clinic Hillcrest Hospital OB/GYN Grand Rounds, Cleveland, Ohio. June 21, 2012.

"The NAMS 2012 Hormone Therapy Position Statement." Annual Meeting of The North American Menopause Society. Orlando, Florida. October 5, 2012.

"A Proactive Approach to Sexual Dysfunctions." Resident Awardees at the Annual Meeting of The North American Menopause Society. Orlando, Florida. October 5, 2012.

"Hormone Therapy Pre and Post the Women's Health Initiative." Advisory Committee on Research on Women's Health. NIH, Bethesda, Maryland. October 15, 2012.

"Managing Perimenopause." Kettering Hospital OB/Gyn Grand Rounds, Kettering, Ohio. November 2, 2012.

"The Women's Health Initiative a Decade Later." International Society of Clinical Densitometry Annual Meeting. Tampa, Florida, March 21, 2013.

"Managing Perimenopause." SIGMA Canadian Menopause Society Inaugural Meeting. Ottawa, Canada, May 4, 2013.

"New Nomenclature and a New Staging Tool for Vulvovaginal Atrophy." Annual Meeting of The North American Menopause Society. Dallas, Texas, October 12, 2013.

"Vulvovaginal Atrophy – Opening the conversation about sexuality during menopause." Association of Reproductive Health Professionals. Charlotte, NC. September 20, 2014.

"Hormone Therapy – Where have we been, Where are we going?" Grand Rounds, University of Texas Health Science Center at Tyler. Tyler, Texas. December 4, 2014.

"The Case Against Hormone Therapy for Prevention." A Debate. Southwestern Gynecology Assembly, Dallas Texas. December 5, 2014.

Panelist, *Pharmacist's Letter VOICES: Clinical Recommendations (PLV-CR)* webinar, January 20, 2015.

"Hormone Therapy Then, Now, and Next." Grand Rounds Magee Women's Hospital Department of Obstetrics and Gynecology. Pittsburgh, PA. February 10, 2015.

"Menopause and Osteoporosis - What's a clinician to do?" Duke Medicine's Second Regional Women's Health Conference, Raleigh, NC, April 11, 2015.

"Treatments for Reduced Sexual Desire/Arousal in Women Gynecological Perspective " Food and Drug Administration Symposium at the American Society of Clinical Psychopharmacology Annual Meeting. Miami, Florida. April 25, 2015.

"The International Dilemma on MHT: How long? How much? NAMS position" SIGMA Canadian Menopause Society. Toronto, Canada. September 12, 2015.

"What Happens Down There?" SIGMA Canadian Menopause Society. Toronto, Canada. September 12, 2015.

"The American Perspective on the Value of Organizational Relationships." Federation of Medical Women of Canada. Toronto, Canada. September 27, 2015.

"Use of Compounded Hormone Therapy in the United States." The North American Menopause Society Annual Meeting. Las Vegas. October 3, 2015.

Menopause Panel on use of hormone therapy: Case presentation of hormone therapy over age 65 years. International Society for the Study of Women's Sexual Health. Charleston, SC, February 26, 2016.

"Does Menopausal Hormone Therapy Still Have a Role to Play in Osteoporosis Management?" National Osteoporosis Foundation Interdisciplinary Symposium on Osteoporosis. Miami, FL. May 14, 2016.

"Does Hormone Therapy Still Have a Role to Play in Osteoporosis Management? Albuquerque Bone Club. Albuquerque, NM. October 27, 2016.

"Hormone Therapy and Sexual Function in Women Ages 55-85." The Serbian Menopause Society. Belgrade, Serbia. November 17, 2017.

"The Prevention of Osteoporosis with Hormone Therapy Debate." International Menopause Society. Vancouver, Canada. June 7, 2018.

"Effects on Sexual Function in Older Women Discontinuing Hormone Therapy." International Menopause Society. Vancouver, Canada. June 8, 2018.